Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations

Simply Wall St.01-23

AdvertisementMadrigal’s new Pfizer license puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605441815?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-23 06:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605441815","market":"us","top_or_hot":-1,"title":"Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementMadrigal’s new Pfizer license puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals (MDGL) Valuation After New Pfizer License For Ervogastat In MASH Therapy Combinations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 06:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementMadrigal’s new Pfizer license puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456855351.SGD","symbol_name":"JPMorgan Funds - Global Equity A (acc) SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic","article_id":"2605441815","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-valuation-after-new-pfizer-lic","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605441815","pubTimestamp":1769121406,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Madrigal’s new Pfizer license puts MASH combinations in focus\nMadrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer for ervogastat, a clinical stage DGAT 2 inhibitor aimed at MASH combination therapies.\nThe deal ties Madrigal’s existing MASH franchise to a potential companion drug that targets triglyceride assembly and liver fat. This pairing is one investors may watch closely as the company outlines its plans at the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","MDGL":"Madrigal Pharmaceuticals, Inc.","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4592":"伊斯兰概念","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4568":"美国抗疫概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4550":"红杉资本持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4588":"碎股","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","BK4599":"减肥药","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4534":"瑞士信贷持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4139":"生物科技","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A"},"translate_title":"辉瑞获得Ervogastat用于MASH治疗组合的新许可后，Madrigal Pharmaceuticals(MDGL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.96},"content_text":"AdvertisementMadrigal’s new Pfizer license puts MASH combinations in focus Madrigal Pharmaceuticals (MDGL) has moved into the spotlight after signing an exclusive global license agreement with Pfizer for ervogastat, a clinical stage DGAT 2 inhibitor aimed at MASH combination therapies. The deal ties Madrigal’s existing MASH franchise to a potential companion drug that targets triglyceride assembly and liver fat. This pairing is one investors may watch closely as the company outlines its plans at the upcoming J.P. Morgan Healthcare Conference. See our latest analysis for Madrigal Pharmaceuticals. The Pfizer license news arrives after a volatile stretch for Madrigal’s share price, with a 17.3% decline over the past month, an 18.16% 90 day share price return, and a 46.42% total shareholder return over the past year, alongside a new Chief Accounting Officer appointment and related equity award. If you are watching how MASH focused names are evolving, it could be a good moment to scan other healthcare stocks that might fit your watchlist next. With Madrigal trading at US$498.04 and sitting about 27% below the average analyst price target, yet already posting a 46.4% one year total return, is this still an entry point, or is the market already pricing in future growth? Price-to-Sales of 15.2x: Is it justified? On a P/S basis, Madrigal currently trades at 15.2x, which screens as cheaper than its estimated fair P/S of 20.4x and below the latest close of US$498.04 when you map that multiple back to sales. The P/S ratio compares the company’s market value to its revenue and is often used when a business is still loss making, as is the case here. For a MASH focused biotech with early commercial revenue and ongoing investment, a higher P/S can reflect expectations around future uptake and margin improvement rather than current profitability. What stands out is that Madrigal’s 15.2x P/S is below the 20.4x level our fair ratio work suggests the market could move toward. However, it is higher than the broader US Biotechs industry average of 11.4x. That combination signals investors are paying a premium to the sector but at a discount to where regression based fair value estimates sit for this revenue profile. Explore the SWS fair ratio for Madrigal Pharmaceuticals Result: Price-to-Sales of 15.2x (UNDERVALUED) However, the story can shift quickly if MASH uptake slows or if ongoing losses, including the recent US$289.125 million net loss, weigh more heavily on sentiment. Find out about the key risks to this Madrigal Pharmaceuticals narrative. Another View: Big Gap on Cash Flows While the P/S work suggests Madrigal screens as good value, our DCF model paints an even stronger picture. With the shares at about US$497 and our future cash flow value estimate at US$1,827, the stock screens as very undervalued on this approach. Could that kind of gap really persist if the story plays out as forecast? Look into how the SWS DCF model arrives at its fair value. MDGL Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Madrigal Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 883 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Madrigal Pharmaceuticals Narrative If this framework does not quite fit how you see Madrigal, you can review the same data points yourself and shape a custom thesis in just a few minutes with Do it your way. A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you want to stress test your thinking beyond Madrigal, use the Simply Wall St Screener to quickly surface fresh ideas that match your style and risk appetite.  Spot potential mispricings by scanning these 883 undervalued stocks based on cash flows that might sit below their estimated worth based on cash flows and fundamentals. Tap into powerful growth themes by checking out these 24 AI penny stocks that are tied to artificial intelligence and related technologies. Add targeted income ideas to your watchlist with these 13 dividend stocks with yields > 3% offering yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605441815","isCrawlerRequest":true}